WuXi AppTec (2359.HK) — The CRDMO Anchor of China's Pharma Rally — Quick Take

Asia's largest pharma CRDMO reaccelerates as US supply-chain pressure meets industry pushback — Quick Take

Why This Company Now

Healthcare is the dominant sector on both Sazabi AI screeners on 18 Aug — 8 of 50 HK VolumeSurge names and 12 of 26 US VolumeSurge names — and the catalyst is explicit: SCMP's 17 Aug headline "China's pharma contractors rally on pushback to US supply chain pressure" reported WuXi AppTec H-shares climbing 3% to a record HK$203.40. WuXi AppTec is the anchor and largest-cap name of that CXO complex, and it just delivered a blowout H1 2026 (revenue +38.9%) with full-year guidance raised to +35–39% — a genuine reacceleration colliding with a geopolitical sentiment reversal.

Financial Snapshot

*2025 net profit (CAS) includes one-off gains from the WuXi XDC stake sale and clinical-research divestiture; adjusted non-IFRS net profit was RMB 14.96B (+41.3%). Adjusted non-IFRS gross margin expanded from 48.2% (2025) to 53.9% (H1 2026); adjusted non-IFRS net margin rose to 40.0%. H1 2026 backlog for continuing operations was RMB 66.4B, +25.2% YoY. All figures RMB.

Bull vs Bear

Year	Revenue	Rev Growth	Net Profit
2022	RMB 39.4B	+72%	RMB 8.8B
2023	RMB 40.3B	+2.5%	RMB 9.6B
2024	RMB 39.2B	−2.7%	RMB 9.4B
2025	RMB 45.5B	+15.8%	RMB 19.2B*
H1 2026	RMB 28.9B	+38.9%	RMB 11.1B

✅ Bull Case

Growth reacceleration is real: H1 2026 revenue +38.9% (continuing ops +48%), and full-year guidance was raised to RMB 58.5–60.5B — 35–39% continuing-ops growth, up from 18–22% — as customer drugs succeed and the "follow the molecule" CRDMO model compounds.
Record margins + visibility: adjusted non-IFRS gross margin +9.4pts to 53.9%, net margin +9.7pts to 40%, and a RMB 66.4B backlog (+25.2%) provide both operating leverage and multi-year revenue line-of-sight.
Geopolitical tailwind reversal: ~80% of US biopharma works with Chinese CDMOs and the industry is resisting decoupling; the DoD 1260H listing is being challenged in court as "erroneous," and the market is re-rating the whole complex as the threat recedes.

🔴 Bear Case

Regulatory overhang is not gone: the 1260H designation plus the BIOSECURE Act in the FY2026 NDAA could still restrict US federal contracts and give Western customers cover to dual-source away from WuXi.
Valuation leaves little margin: the stock sits at a record high at roughly 25x forward / ~37x trailing adjusted earnings after a huge run — most of the good news is already priced in.
Capacity ramp risk: 2026 capex was raised to RMB 7.5–8.5B with the new Changzhou site accelerated, which can compress margins during heavy expansion; high customer concentration and 465 audits in H1 underscore execution and scrutiny intensity.

Verdict

WuXi AppTec is the largest-cap, purest way to express the "China pharma contractors rally" — a genuine earnings reacceleration (+39% growth, record margins, RMB 66B backlog) meeting a geopolitical sentiment turn. The risk is that the 1260H/BIOSECURE overhang is more than "erroneous," and the multiple already assumes continued execution. Interesting here for a momentum-aware position with a tight leash on US policy headlines: the fundamental engine is firing, but it isn't cheap.